Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Genitourinary Drugs Market, a vital pharmaceutical area, is dynamically affected by several variables. Genitourinary medications treat urine and reproductive concerns such urinary tract infections, erectile dysfunction, and prostate diseases. Demographic changes, technology advances, regulatory environments, and the ever-changing healthcare sector affect this segment's market dynamics.
The worldwide aging population shapes the genitourinary medicines industry. BPH and erectile dysfunction medicines are in demand as people age due to the rise in genitourinary illnesses. Lifestyle factors such sedentary lifestyles, poor diets, and stress increase the occurrence of urinary and reproductive system problems, driving the market.
Technological advances also affect genitourinary medication markets. Gene treatments, precision medicine, and sophisticated drug delivery methods improve genitourinary disease therapy. These advances enhance patient outcomes and attract R&D expenditures, growing the industry.
Genitourinary medication markets are also shaped by regulations and healthcare policy. New medicine approvals are influenced by strict health authority rules. Genitourinary medication accessibility is also affected by reimbursement and price rules, which affect market growth and novel therapy uptake.
The dynamic genitourinary medicines industry is further fueled by the shift toward patient-centered care and customized therapy. Market growth is driven by pharmaceutical firms' innovation and development of targeted therapeutics to meet patient demands and preventative measures.
Pharmaceutical firms compete fiercely in genitourinary medications. Companies differentiate their goods through efficacy, safety, and patient-friendly administration. Market actors use strategic alliances, partnerships, and mergers and acquisitions to improve their positions, extend their product ranges, and seize new possibilities.
Economic issues like healthcare spending and affordability affect market dynamics. Genitourinary medication accessibility in emerging economies is crucial, and corporations adjust their strategy to varied economic situations and healthcare infrastructures.
Genitourinary Drugs Market Highlights:
Genitourinary Drugs Market Overview
The genitourinary medicines market is estimated to be worth USD 72.9 billion by the end of the forecast period, with a CAGR of 3.6% (2023-2032). Damage to the urinal or genital parts of the human body causes genitourinary diseases. The genitourinary system includes the kidney, bladder, ureter, and urethra, and genitourinary medications are used to address medical issues caused by these organs. The rising prevalence of genitourinary illnesses, increased pipeline drug development, and technological innovation in genitourinary diagnostics are projected to fuel market expansion.
According to the National Library of Medicine in the United States, more than 480 clinical studies are planned for the treatment of urinary tract infections. Center for Health Information, Furthermore, increased R&D investment and collaborative methods used by the industry's leading competitors, such as licensing and partnerships, are driving market expansion.
Genitourinary Drugs Market Segmentation
The genitourinary drugs market has been segmented on the basis of disease, product, and end-user.
On the basis of disease, the market has been classified urinary tract infections, erectile dysfunction, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, prostate cancer, and others.
The product segment has been divided into urologicals, hormonal therapy, gynecologicals, and anti-infectives.
The market, by end-user, has been segmented into hospitals, clinics, super specialty centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The genitourinary drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European genitourinary drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The genitourinary drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The genitourinary drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.
Genitourinary Drugs Market Regional Analysis
The Americas are likely to dominate the genitourinary drugs market owing to the rising prevalence of genitourinary disorders in aging population, increase in the healthcare expenditure, and the presence of a well-established healthcare system. According to the National Kidney Foundation, Urinary tract infections (UTIs) are responsible for nearly 10 million doctor visits each year and approximately 20% women suffer from UTI at least once in a life.
The European market is expected to be the second-largest genitourinary drugs market. The market growth in this region can be attributed to the increasing research and development, rise in number of chronic diseases such as diabetes, and government initiatives for the development of healthcare sector. According to the International Diabetes Foundation, diabetes is major health concern in European region and in 2017, approximately 9.1% of total European population was suffering from diabetes.
Asia-Pacific is expected to be the fastest-growing genitourinary drugs market during the forecast period owing to the increasing geriatric production along with rise in number of genitourinary disorders, rising investments in healthcare and expansions by market players in the region. According to United Nations, Department of Economic and Social Affairs, in 2016, 12.4% of total population in Asian countries was 60 year or older.
The market in the Middle East & Africa is expected to hold the smallest share of the genitourinary drugs market due to lack of technical knowledge, undeveloped healthcare sector, and poor medical facilities.
Genitourinary Drugs Disease Outlook
- Urinary Tract Infections
- Urinary Incontinence & Overactive Bladder
- Kidney/Renal Cancer
- Genitourinary Cancer
- Bladder Cancer
- Cervical Cancer
- Sexually Transmitted Diseases
- Interstitial Cystitis
- Hematuria
- Ovarian Cancer
- Prostate Cancer
- Others
Genitourinary Drugs Product Outlook
- Urologicals
- Hormonal Therapy
- Gynaecologicals
- Anti-Infectives
- Others
Genitourinary Drugs End-User Outlook
- Hospitals
- Clinics
- Super Specialty Centers
- Others
Genitourinary Drugs Region Outlook
- Americas
- North America
- US
- Canada
- South America
- North America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- The Middle East & Africa
- Middle East
- Africa
Company Profiles
- Abbott
- Astellas Pharma Inc.
- AstraZeneca
- Pfizer Inc.
- Eli Lilly and Company
- Genentech, Inc.
- Immunex Corp.
- GlaxoSmithKline plc.
- Ionis Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Bristol-Myers Squibb Company
- Antares Pharma
- Bayer AG
Recent Development
November 2023
Pfizer announces positive results from a Phase 3 clinical trial of its investigational drug, PF-06939999, for the treatment of overactive bladder (OAB). The trial showed that PF-06939999 was significantly more effective than placebo in reducing the number of urge urinary incontinence (UUI) episodes and the number of times patients urinate per day.AstraZeneca announces that it has received FDA approval for its drug, Lynparza® (olaparib), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA1 or BRCA2 mutation. Lynparza® is the first PARP inhibitor to be approved for the treatment of mCRPC with a BRCA1 or BRCA2 mutation.Merck & Co., Inc. announces that it has submitted a New Drug Application (NDA) to the FDA for its investigational drug, KEYTRUDA® (pembrolizumab), for the treatment of patients with locally advanced or unresectable urothelial carcinoma (UC) who have progressed on or following platinum-based chemotherapy. KEYTRUDA® is an immunotherapy drug that targets PD-1, a protein that helps cancer cells evade the immune system.
October 2023
Bristol Myers Squibb Company announces that it has received FDA approval for its drug, Opdivo® (nivolumab), in combination with Yervoy® (ipilimumab), for the treatment of patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed on or following anti-angiogenic therapy. Opdivo® and Yervoy® are immunotherapy drugs that target PD-1 and CTLA-4, respectively.GSK announces that it has received FDA approval for its drug, ViiV Healthcare's Cabenuva®, for the first-time treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen. Cabenuva® is a long-acting injectable combination of cabotegravir and rilpivirine that is administered once every two months.
September 2023
Johnson & Johnson announces that it has submitted an NDA to the FDA for its investigational drug, Erleada® (apalutamide), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Erleada® is a nonsteroidal androgen receptor antagonist (AR) inhibitor that is designed to block the growth of prostate cancer cells.Sanofi announces that it has received FDA approval for its drug, Dupixent® (dupilumab), for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients who are candidates for systemic therapy. Dupixent® is a biologic drug that targets the IL-4 and IL-13 signaling pathways, which play a role in the inflammation associated with atopic dermatitis.
Intended Audience
- Pharmaceutical Industry
- Healthcare providers
- Medical device manufacturers
- Research institutes and academic centers
- Contract research organizations (CROs)
- Government associations
- Market research and consulting
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
